Acomplia
Acomplia, contains Rimonabant, a compound that is considered a breakthrough drug
in battling obesity, and smoking addiction.Acomplia is a cannabinoid receptor
antagonist. In other words, the normal action of endogenous cannabinoid in the
brain is prevented from motivating the CB1 receptors, (which are responsible for
stimulating appetite). These receptors are thought to be more active in
overweight people. Therefore, blocking them may have a normalizing effect,
making the urge to satisfy hunger less critical.
Benefits of Acomplia
Clinical trials have shown that these receptor sites may also potentially help
people to stop smoking. Acomplia may reduce the likelihood of weight re-gain,
and studies have demonstrated improvements in metabolism, cholesterol and
cardiovascular risk factors.
Human trials have shown an average loss of 10% bodyweight, a large proportion of
which was lost from the mid-section (or abdominal cavity). The average figures
from the trials show fat loss of 20 lbs (9 kg) and 3 inches (8 cm) from the
waist, and the loss has been maintained for up to 2 years.
Further trials have been undertaken to help smokers kick the habit. Early
studies suggest that Acomplia may double the chances of quitting smoking
permanently, while potentially not gaining excess weight as a result.
Current product details